PDA Letter
Home / PDA Letter / Biopharmaceuticals & Biotechnology

Biopharmaceuticals & Biotechnology

Viruses on the Surface

Jennifer Loughman and Paul Lopolito, STERIS

Can the Power of Viruses be Harnessed for Good?

Brian Hawkins, PhD, Pluristyx, Inc.

Biopharma Offers New Opportunities

Cristiana Campa, GSK, and Michael De Felippis, Eli Lilly and Company

How to Best Tackle Biosimilar Challenges

Stephan Krause, PhD, AstraZeneca Biologics, and Jens Schletter, PhD, Novartis

Getting Biosimilars Right the First Time

Barbara Rellahan, Amgen

Knowledge Grows for mAb Development

Martijn van der Plas, PhD, Medicines Evaluation Board, and Michael De Felippis, PhD, Eli Lilly

RMAT Program Raises a Few Questions

Austin Caudle, IQVIA

Speaking the Language of GMP

Rebecca Stauffer, PDA

Know Your Numbers for Analytical Similarity

Emanuela Lacana, PhD, U.S. FDA

Cell and Gene Therapies Present Challenges, Promise

Joshua Eaton, PDA

New Approach Suggests Continuous Lyophilization is Possible

Pieter-Jan Van Bockstal, Ghent University, Jos Corver, RheaVita, and Thomas De Beer, Ghent University

The Future of Cell and Gene Therapies is Here

Austin Caudle, Metabolon, Inc.

How to Get Your ATMP From the Lab to the Market

Andy Fry, Team Consulting

Viral Safety Approaches for Advanced Therapy Medicinal Products

Thomas R. Kreil, PhD, Global Pathogen Safety, Shire